Poor
Not Aligned
Patient Risk:
Low
Summary
The provided AI statements are about FDA approval timing/expansion rather than Avastin’s labeled indications, dosing/administration, contraindications, warnings, or safety. The supplied label excerpts do not support these claims, and they are not verifiable against the provided prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
FDA approval of bevacizumab (Avastin) began in the mid-2000s.
The supplied label excerpts do not mention FDA approval dates or approval timeline. No label support for the claimed timing.
The first FDA approval of bevacizumab was granted in 2004 for use in cancer.
The supplied label excerpts do not provide first-approval date information. No label support for this year or claim.
In 2004, bevacizumab received initial FDA approval for cancer treatment.
The supplied label excerpts do not provide initial FDA approval year or basis. No label support.
New drugs can receive initial approval and then later get expanded to additional indications.
This is a general regulatory statement not stated or supported within the provided prescribing information excerpts.
Contradictions
Important Omissions
No Avastin-specific on-label information (e.g., which indications, dosing regimens, contraindications, or labeled warnings/precautions) is provided for evaluation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated AI statements do not contain prescribing, dosing, contraindication, or safety-management instructions that could directly lead to incorrect patient treatment based on the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims focus on FDA approval timing and general regulatory processes that are not supported by the provided Avastin FDA prescribing information excerpts.
Suggested Improvement
If the goal is label alignment, replace approval-timeline statements with claims grounded in the label sections provided (e.g., specific Avastin indications, labeled dosing regimens, contraindications, and labeled warnings/precautions such as GI perforation, wound healing complications, hemorrhage, thromboembolic events, hypertension, and proteinuria).